Twist Bioscience Launches Human Methylome Panel to Enable Detection of Methylation Fractions in a Diverse Range of Applications
May 31 2022 - 7:00AM
Business Wire
Panel covers 84.2% of CpG islands
New tool supports discovery of differentially
methylated regions and epigenetic target identification for cancer
metastasis and human development research
Human methylome panel facilitates development
of liquid biopsy panels
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the launch of the
Twist Human Methylome Panel, a product now available to customers
that can advance applications in cancer metastasis, human
development and functional genetics. The panel can be used to
identify a robust, collated set of CpG sites, methylated cytosine
and guanine nucleic bases, across the human genome to identify
biologically relevant methylation markers. Compared to traditional
array based or whole genome bisulfite sequencing approaches, this
panel provides overall cost savings while also covering previously
unknown methylation markers. The Twist Human Methylome Panel can
also be used as a first pass discovery tool to identify methylation
biomarkers that can then be used in a variety of applications, such
as more targeted liquid biopsy panels.
The DNA methylome is the comprehensive set of nucleotides within
the genome that have a methyl group attached. DNA methylation plays
a key role in many biological processes, including cancer. When
present on a single nucleotide, a methyl group can alter genetic
behavior without changing the DNA sequence. Analyzing the pattern
in which methylation occurs within a specific genetic sequence as
well as the fraction of the genome that has a methyl group attached
(methylated) provides a unique understanding of disease pathology.
CpG sites, which often repeat to create CpG islands, turn a gene
“on” or “off” and are associated with neurodegeneration, cancer and
multiple rare diseases. Detection of CpG islands therefore can
inform diagnoses or development stage of multiple diseases.
The Twist Human Methylome Panel is highly targeted to capture
and detect the most recently identified and relevant CpG
methylation regions in the genome. Twist uses hybrid capture panels
to explore the methylome and the content that can be investigated
to include 84.2% of CpG islands as well as other CpG sites.
“With the customizable Twist Human Methylome Panel, we are able
to cover four times the amount of CpG sites compared to average
microarrays. Using our NGS-based panel provides a higher dynamic
range, allowing more accurate identification of differentially
methylated regions, which we believe will enhance research-based
assays and diagnostic tests that incorporate this dynamic tool,”
said Emily M. Leproust, Ph.D., CEO and co-founder of Twist
Bioscience. “Previously, when identifying methylation markers,
researchers had to choose between a low-cost, static option or a
very expensive panel that covers a significant portion of the
methylome, but often more than needed. As technology progresses,
the compromise that researchers need to make between cost and
coverage becomes less and less.”
“We look forward to expanding our work with Twist as well as
extending our epigenomics expertise and offerings to customers by
incorporating the Twist Human Methylome Panel into our Epigenomics
Profiling Services. This aligns with our efforts to continue
offering new solutions to link methylation research with a wide
range of disease indications and progression,” said Didier Allaer,
CEO of Diagenode, a leading epigenomics company and early access
customer for the Twist Human Methylome Panel. “The new panel will
enable us to offer a solution with broad coverage of the human
methylome and to bring epigenetics research to new frontiers of
biomarker discovery on clinical samples.”
About Twist Human Methylome Panel
The Twist Human Methylome Panel enables the identification and
study of methylation biomarkers spanning a wide range of targets
and applications. The 123 megabase panel covers 84.2% of CpG island
sites contained within the human genome and is optimized with the
Twist Methylation workflow for robust end-to-end performance. The
high capture efficiency increases the sensitivity of detection and
internal data show that the Twist Human Methylome Panel achieves a
depth of coverage of 90% of bases at 30x coverage with high probe
specificities of 95% on-target rates, as well as high uniformity
across the target region.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements,
including the potential for the Twist Human Methylome Panel to
advance applications in cancer metastasis, human development and
functional genetics. All statements other than statements of
historical facts contained herein are forward-looking statements
reflecting the current beliefs and expectations of management made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks, uncertainties, and other important factors
that may cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. For a description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Twist Bioscience’s business in general, see Twist
Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission on May 6, 2022 and subsequent filings with the SEC. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220531005304/en/
Twist Bioscience Angela Bitting SVP, Corporate Affairs
925- 202-6211 abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024